Table 1.
Demographic and clinical characteristics of the patients with primary Sjögren’s syndrome included in the study
| Patients (n = 51) | |
|---|---|
| Age (years) | 60 ± 12 |
| Female patients N (%) | 49 (96) |
| Disease duration (years) | 17 ± 12 |
| Current/prior/never smokers N (%) | 4/20/27 (8/39/53) |
| Anti-SS-A antibody seropositives N (%) | 40 (78) |
| Anti-SS-B antibody seropositives N (%) | 24 (47) |
| ANA seropositives N (%) | 40 (78) |
| RF seropositives N (%) | 26 (51) |
| IgG (g/L) | 13.8 ± 5.1 |
| C3 (g/L) | 1.03 ± 0.25 |
| C4 (g/L) | 0.18 ± 0.07 |
| Focus score ≥1 (positive/negative/not assessed) N (%) | 37/3/11 (73/6/22) |
| ESSDAI total score | 7 ± 6 |
| ESSPRI total score | 6 ± 2 |
| Fulfilling GOLD criteria for COPD N (%) | 21 (41) |
| VC (L) | 3.3 ± 0.8 |
| FEV1 (L) | 2.3 ± 0.6 |
| FEV1/VC ratio | 0.69 ± 0.08 |
| D L CO (mmol/min kPa) | 6.5 ± 1.9 |
| Radiographic signs of ILD of the below N (%) | 9 (18) |
| Peripheral traction bronchiectasias N (%) | 4 (8) |
| Ground glass opacities N (%) | 6 (12) |
| Honey combing N (%) | 0 (0) |
Results are presented as mean ± SD or as absolute numbers (% with abnormal findings)
GOLD Global Initiative for Chronic Obstructive Lung Disease, COPD chronic obstructive pulmonary disease, VC vital capacity, FEV 1 forced expiratory volume in 1 s, D L CO diffusion capacity for carbon monoxide